Purchase this article with an account.
G. Heilweil, I. Komarowska, R. L. Avery, M. Goldstein, I. Perlman, A. Loewenstein; Pharmacokinetics of Bevacizumab After Single Intravitreal Injection in the Rabbit. Invest. Ophthalmol. Vis. Sci. 2007;48(13):92.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the pharmacokinetics and serum bioavailability of intravitreal bevacizumab in the rabbit.
12 albino rabbits were intravitreally injected to one eye with bevacizumab1.25mg/0.05ml. One rabbit served as intact control. Vitreous samples were taken 1, 2 ,4, 6 weeks after injection, 3 rabbits for each time point. Blood samples were taken 2 and 6 weeks after injection. Bevacizumab concentrations in the plasma and vitreous were determined by enzyme-linked immunosorbent assay (ELISA).
The mean vitreal concentration of bevacizumab decreased by 37%, 62%, 70% and 81% at the 1,2,4 and 6 weeks respectively. Mean vitreal concentration in the uninjected eye was 4.93 ng/ml, 4.36ng/ml, 1.06ng/ml and 0.41ng/ml at the 1,2,4,6 weeks respectively. Mean plasma concentrations of bevacizumab was 17.20 pg/ml, and 7.02 pg/ml at the 2 and 6 weeks respectively. Mean vitreal and plasma concentrations of the control rabbit were lower than the sensitivity of the assay.
The mean half life of bevacizumab in the rabbit eye was 10 days. The high intravitreal concentrations observed after 6 weeks demonstrates a lower than expected turnover of bevacizumab. The concentration of bevacizumab in the plasma and uninjected eye indicates systemic circulation.
This PDF is available to Subscribers Only